© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
November 27, 2020
Intermittent hypoxia sensitizes control centers in the brain, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.
Clinicians must make sure patients are engaged in their care, stressed Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy.
If results from FIGARO-DKD are as positive as those of FIDELIO-DKD, the field will work aggressively to get the message out, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
November 26, 2020
Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
November 25, 2020
Lurbinectedin is being studied in a number of diseases, but in lung cancer it has a more favorable side effect profile compared with topotecan, said Apar Kishor Ganti, MD, University of Nebraska Medical Center.
Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
November 23, 2020
In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this care.
Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.
November 22, 2020
The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
November 21, 2020
In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.